Oramed Pharmaceuticals Inc. ORMP

ORMP Company Overview

Oramed Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on the development of oral drug delivery platforms for peptide-based therapeutics, particularly insulin and other protein-based drugs that are traditionally administered by injection. The company operates within the biopharmaceutical and diabetes-treatment industries and has historically centered its research on oral formulations intended to improve patient compliance and expand accessibility for chronic disease management. Its core technology platform is designed to protect protein-based drugs from degradation in the gastrointestinal tract and facilitate absorption into the bloodstream.

The company’s primary business activities have included development of oral insulin capsule candidates and related delivery technologies. Oramed has also expanded its strategic focus beyond therapeutic development through investments and corporate transactions tied to biotechnology and healthcare-related opportunities. Founded in 2006 and headquartered in Jerusalem, Israel, the company evolved from an early-stage drug delivery research venture into a Nasdaq-listed biotechnology company. Public filings and investor materials indicate that Oramed’s positioning has relied on proprietary oral delivery technology, intellectual property protections, and partnerships aimed at advancing clinical development and commercialization opportunities.